Impact of glucagon-like peptide-1 receptor agonists on bowel preparation quality for colonoscopy in type 2 diabetes

Figure 1 Flowchart of study population selection for glucagon-like peptide-1 receptor agonist users and propensity score-matched controls. GLP-1RAs: Glucagon-like peptide-1 receptor agonists; DPP-4: Dipeptidyl peptidase-4; T2DM: Type 2 diabetes mellitus; GI: Gastrointestinal; BMI: Body mass index; HbA1c: Hemoglobin A1c; CKD: Chronic kidney disease.

Figure 2 Incidence of inadequate bowel preparation by colonic segment in the matched cohort. DPP-4i: Dipeptidyl peptidase-4 inhibitor; GLP-1RA: Glucagon-like peptide-1 receptor agonists.

Figure 3 Distribution of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor subtypes among matched-cohort patients with inadequate bowel preparation. A: Distribution of glucagon-like peptide-1 receptor agonist subtypes; B: Distribution of dipeptidyl peptidase-4 inhibitor subtypes. DPP-4: Dipeptidyl peptidase-4; GLP-1RAs: Glucagon-like peptide-1 receptor agonists.